Passage Bio, Inc. filed a Form 8-K on November 6, 2026, reporting the results of a Special Meeting of Stockholders held on November 5, 2026, at which stockholders approved equity compensation plans and merger-related proposals connected to the company's planned combination with Remix Therapeutics, Inc.
Key Highlights
- Special Meeting held: Passage Bio stockholders convened on November 5, 2026, with 2,318,821 of 3,217,810 eligible shares represented, constituting a quorum.
- 2026 Equity Incentive Plan approved: The plan initially reserves 5,772,500 shares (before the proposed Reverse Stock Split) and includes an annual increase of up to 5% of outstanding shares beginning January 1, 2027, through January 1, 2036.
- Incentive stock option cap: No more than 17,317,500 shares (before the proposed Reverse Stock Split) may be issued under the 2026 Plan upon exercise of incentive stock options.
- 2026 ESPP approved: The Employee Stock Purchase Plan authorizes up to 440,000 shares initially (before the proposed Reverse Stock Split), plus an annual increase of up to 1% of outstanding shares or 880,000 shares, whichever is less, beginning January 1, 2027.
- Remix option conversion ratio: Each outstanding Remix stock option will convert into a Passage Bio option at an assumed exchange ratio of 0.1727, subject to adjustment for the proposed Reverse Stock Split.
- Merger Agreement parties: The merger involves Passage Bio, Peregrine Merger Sub, Inc., Peregrine Merger Sub II, LLC, and Remix Therapeutics, Inc., under an agreement dated September 2, 2026, and further amended October 5, 2026.
- Record Date: Only stockholders of record as of September 30, 2026, were entitled to vote at the Special Meeting.
Passage Bio Stockholders Vote on Remix Merger and New Compensation Plans
According to the filing, Passage Bio (NASDAQ:PASG) held a Special Meeting of Stockholders on November 5, 2026, to consider proposals arising from its planned merger with Remix Therapeutics, Inc. The merger structure, as described in the filing, involves two steps: first, Peregrine Merger Sub, Inc. will merge with and into Remix, leaving Remix as a wholly owned subsidiary of Passage Bio; immediately after, Remix will merge with and into Peregrine Merger Sub II, LLC, which will survive as a wholly owned subsidiary of Passage Bio.
At the Special Meeting, stockholders approved the Remix Therapeutics, Inc. 2026 Equity Incentive Plan, which the filing states is intended to replace Passage Bio's 2018 Equity Incentive Plan, Passage Bio's 2020 Equity Incentive Plan, and Remix's 2019 Equity Incentive Plan. The 2026 Plan will become effective at the Initial Effective Time of the First Merger and is contingent on completion of that merger. The filing notes that upon the effective date of the 2026 Plan, no new awards will be granted under the prior plans, though previously granted awards will remain subject to their original plan terms. The Remix 2019 Plan, together with all outstanding awards under it, will be assumed by Passage Bio in the First Merger.
Stockholders also approved the Remix 2026 Employee Stock Purchase Plan at the same meeting. The 2026 ESPP will become effective at the Initial Effective Time and allows shares to be used to satisfy purchases under a Section 423 component and a non-Section 423 component, according to the filing. The filing states that shares under both plans may consist of authorized but unissued shares, treasury shares, or shares purchased on the open market. A more complete description of both plans, the filing notes, is set forth in Passage Bio's definitive proxy statement/prospectus filed with the SEC on October 9, 2026.
What Was Disclosed
Passage Bio reported stockholder approval of two new equity compensation plans and voting results from its November 5, 2026, Special Meeting, all tied to the pending two-step merger with Remix Therapeutics, Inc. under a merger agreement dated September 2, 2026, and amended October 5, 2026.





Please wait processing your request...